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ABSTRACT
The identification of novel biomarkers of cancer is important for improved 
diagnosis and prognosis. With an abundant amount of resources in the publicly 
available database, such as the Cancer Genome Atlas (TCGA) database, an integrative 
strategy is used to systematically characterize the aberrant patterns of colorectal 
cancer (CRC) based on RNA-Seq, chromatin immunoprecipitation sequencing 
(ChIP-Seq), tissue microarray (TMA), gene profiling and molecular signatures. The 
expression of the transcription factor ATF3 was elevated in human CRC specimens 
in a TMA by immunochemistry analysis compared to the adjacent normal tissues. 
In addition, ATF3 overexpression associated with a regulatory molecular signature, 
and its functions are related to the pathogenic development of CRC. Furthermore, 
putative ATF3 regulatory elements were identified within the promoters of ATF3 
target genes and were confirmed by ChIP-Seq. Critically, in higher ATF3 expression 
cell lines (HCT116 and RKO) with CRISPR/Cas9 mediated ATF3 knock out, we are 
able to show that ATF3 target genes such as CEACAM1, DUSP14, HDC, HLF and 
ULBP2, are required for invasion and proliferation, and they are robustly linked 
with poor prognosis in CRC. Our findings have important implications for CRC 
tumorigenesis and may be exploited for diagnostic and therapeutic purposes.
INTRODUCTION
Colorectal cancer (CRC) is the third most 
common malignant neoplasm in western countries. The 
burden of CRC is increasing in the Asia-Pacific region 
[1]. Its prognosis has been elevated gradually due to 
developing procedures such as surgery, radiotherapy and 
chemotherapy. However, the survival rate of patients 
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with CRC is still very low [2]. The identification of novel 
CRC biomarkers play an important role in making more 
selective treatment decisions.
Significant progress has been made in identifying 
novel molecular signatures to understand CRC subsets 
over the last few years. As a result, the Wnt signaling 
pathway, the RAS pathway, and functional loss of 
tumor suppressor genes (p53 and APC) have been well 
understood [3]. To date, much effort has been made to 
identify biomarkers. However, it has achieved limited 
success because it focused on a single protein or gene 
mutation [4]. More gene signatures and signaling pathways 
of CRC are needed to develop a firmer understanding of 
CRC progression and to improve clinical prognosis and 
therapy.
Recently, high-throughput technologies have 
been developed, and a comprehensive method of 
integrating the information from different technological 
platforms including gene expression profiling and 
genomic sequencing analysis enables us to identify 
gene signatures and the related signaling pathways. 
Using patient tissue genomic, RNA expression data and 
clinical information, the Cancer Genome Atlas (TCGA) 
obtains an overview of cancer related profiles. It can also 
identify potential biomarkers for diagnosis diseases and 
prognosis. With the help of high-throughput sequencing 
technology, bioinformatic methods have been developed 
to identify differential expressed genes from RNA-Seq 
and correlate the regulation of regenerating genes by 
chromatin immunoprecipitation sequencing (ChIP-Seq). 
Additionally, the Kaplan Meier overall survival (OS) 
rates are also integrated [5, 6]. The abundant evidence 
of genetic and expression alterations based on the huge 
number of patient samples, may help us identify the 
relationship between clinical phenotypes and genetic 
expressions more accurately.
The biological and clinical significance of 
an overexpressed transcription factor (Myc) as an 
oncogene and the loss of a transcription factor (p53) as 
a tumor suppressor is that they are dysregulated during 
the initiation, progression and metastasis of CRC [7]. 
However, p53- and Myc-independent regulation also 
exists in CRC signaling through other transcription 
factors, and thus, identifying the key transcription factors 
that regulate the molecular signature associated with CRC 
progression will provide useful predictive markers. The 
activating transcription factor (ATF) family includes 
many basic-region leucine zipper (bZIP) transcription 
factors [8]. The ATF/cyclic AMP response element-
binding (CREB) family members include ATF1, ATF2, 
ATF3, ATF4, ATF5, ATF6, ATF7, B-ATF, CREB and 
CREM. The bZIP element is a common feature of these 
proteins. The basic region in this domain plays the role 
of specific DNA binding, with the leucine zipper region 
forming homodimers or heterodimers with other proteins 
that contain bZIP elements, such as the AP-1, C/EBP or 
Maf families of proteins [8]. Substantial evidence shows 
that ATF3 may play an important role as a host defense 
by balancing the proliferative and apoptotic signals that 
are related with the progression of cancer [9]. It can also 
play various roles in cancer development in different cell 
types and contexts [8, 10]. Importantly, controversial roles 
for ATF3 have been reported. In normal tissues, ATF3 
promotes both apoptosis and cell proliferation [11], while 
in neoplasms it has been identified as either an oncogene 
or a tumor suppressor, depending on the context of tumors 
[10, 12]. Previous studies investigated a limited number of 
cell lines and small cohorts, which were not biologically 
relevant. Thus, the function of ATF3 in tumor progression, 
including metastasis, has not yet been fully characterized. 
Our recent study suggested that ATF3 might play a role 
in bladder cancer metastasis [13]. However, the role of 
ATF3 in either pro-metastasis or anti-metastasis signaling 
remains controversial. These discrepancies are due to 
the context-dependent function of ATF3. Therefore, the 
accurate role of ATF3 in initiation and progression of 
CRC is still unclear. However, the role of ATF3 in CRC 
is paradoxical, with both pro- and anti-tumorigenic roles 
suggested.
In the current study, we systematically integrated 
data from TCGA, GEO and the JASPAR database, 
using RNA-Seq, ChIP-Seq and TMA to identify gene 
signature. Target genes of ATF3 regulation which have an 
important impact on tumor phenotype and prognosis were 
validated by colorectal cell line experiments. Critically, we 
demonstrate that ATF3, with its target genes, is required 
for an invasion tumor cell phenotype and is robustly linked 
with poor prognosis in CRC.
RESULTS
Workflow for the identification of a potential 
prognostic biomarker in CRC
We focused on tumor and adjacent normal tissue 
differences to develop a prognostic expression signature 
for CRC. Firstly, we used the TCGA RNA-Seq expression 
data to conduct a differential expression (DE) analysis 
and found differential expression genes (DEGs). Then, 
we combined the survival data from TCGA to screen the 
DEGs with a significant difference between the low and 
high expression subgroups. To validate the existence of 
ATF3 transcription factor binding sites in the promoter 
region, we used both the ChIP-Seq experimental data 
from GEO and the motif matrix from JASPAR. 47 genes 
were found to influence the survival rate with both a 
computational and experimental prediction of a binding 
site. We then validated the genes in Integrative Genomics 
Viewer (IGV) to find genes with the nearest binding site 
to transcription start site (TSS). Finally, we performed 
univariate and multivariate Cox regression to determine 
the significance level of the candidate genes (Figure 1A).
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Identification of candidate genes for CRC 
outcome
We investigated whether there was a significant 
difference in gene expressions between all the tumor (n = 
478, male 252, female 226) and adjacent normal tissue (n 
= 41, male 20, female 21) samples using limma package 
in RStudio. In total, 2,086 genes were significantly 
differentially expressed between the tumor and adjacent 
normal tissue in both males and females; 527 (25.26%) 
genes were upregulated in both male and female tumor 
tissues, while 1,559 (74.74%) genes were downregulated. 
Figure 1: Identified the candidate genes for outcome of CRC. (A) Flow-chart of the bioinformatic analysis in this research 
was shown. Data were collected from TCGA, GEO and JASPAR database. (B) Heatmap was generated in RStudio. The top right region 
represents the hierarchical clustering results, with red and green bars indicating tumor and adjacent normal samples, respectively. The left 
bottom region represents the 11 DEGs, with red and green bars indicating high and low expression in tumor samples compared to adjacent 
normal samples. (C) KEGG pathway analysis was conducted in RStudio and p value was shown.
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For most genes within this signature, there was a 
decreasing pattern of expression from the adjacent normal 
tissue to the tumor tissue.
Among all the DEGs, we conducted a Kaplan-Meier 
survival analysis that select target genes. We used the 
Benjamini & Hochberg method [14] to conduct multiple 
comparison corrections, but it was too conservative 
(data not shown). Since our downstream analysis and 
experiments can further validate the false positives, 
we used the unadjusted p values, and 148 genes had 
significantly different survival rates between the high- 
and low-expression subgroups. 44 (29.73%) genes were 
upregulated in the tumor, while 104 (70.27%) genes were 
downregulated.
ATF3 presented a binding motif in a subset of 
candidate genes
A total of 2,086 DEGs were input as targets and 
another 1,068 least DEGs that had a log-fold-change 
(log2FC) <0.05 were used as background to eliminate the 
noise due to biological variance. In total, 1,755 genes had 
at least 1 predicted ATF3 binding site in our computational 
prediction. ATF3 was one of the top overrepresented 
transcription factors, and those signature genes had ATF3 
binding sites in their upstream sequences. As a cancer 
prognostic marker, transcription factor STAT3 also 
presented binding sites (Figure 2A).
Meanwhile, the data from ATF3 ChIP-Seq were 
downloaded from the GEO database (GSM1917774_1152) 
for the control group to identify the experimental ATF3 
binding site. The ATF3-WT HCT116 CRC cell line was 
used for the ChIP analysis, and 14,438 genes had a peak 
within a certain range from the TSS. We compared these 
genes (14438 genes) with the outcome genes from the 
computational prediction (1755 genes), and 854 genes 
overlapped with different expressions. Then, we compared 
the 854 genes with the 148 genes with a different survival 
rate; 47 genes overlapped. Information on these 47 genes, 
includes the logFC, p value and adjusted p value for male 
and female groups, p values for survival rates and distance 
to TSS was listed in Supplementary Table 1. Furthermore, 
up to 11 genes were identified with a regulated signature 
after further filtering. Only 9 genes (CEACAM1, PARM1, 
TOMM34, SPTBN2, DUSP14, STC2, CCNJL, ULBP2, 
and C2orf48) had a peak within 10 kbp from TSS, in both 
the computational prediction group and the experimental 
group (Figure 2B). In addition, 2 genes (HLF and HDC), 
which were reported to interact with ATF3, had peaks 
but were either far from the TSS or in the intron. We 
also identified the peaks for the 11 selected ATF3 target 
genes in another experiment from the ENCODE database 
(GSM1010757), and observed that the ChIP-Seq of ATF3 
in HCT-116 cell line with 2 replicates (data not shown). 
Those 11 genes were more likely targeted by ATF3. The 
expression pattern of the 11 genes is shown in heatmap 
(Figure 1B). A KEGG pathway analysis was conducted 
for the 47 genes and the most significant pathways 
were related to cell adhesion molecules and histidine 
metabolism (Figure 1C).
By integrated data analysis from TCGA database 
between the tumor and adjacent normal tissues, we 
subsequently identified candidate genes for CRC outcome. 
The results were also confirmed by the ChIP-Seq from the 
public GEO database [15]. These 11 specific ATF3 target 
genes had very noticeable differences between cancer and 
adjacent normal tissues. There are also some genes that 
are expressed differently between various clinical stages 
(such as STC2 and ULBP2), but most of the expressions 
between the stages (Supplementary Figure 1) only have 
a minimal change. ATF3 and the expressions of its target 
genes will be studied with further validation in a larger 
number of tissues and cell lines to assess their expressions 
and function.
ATF3 regulated target genes in human CRC cells
To further validate ATF3 and the expressions of 
its target genes, ATF3 protein expressions were studied 
in 6 human CRC cell lines. Western blot results revealed 
constitutively higher ATF3 expression in two cell lines 
(HCT116 and RKO), whereas there was no or lower 
expression in the colorectal cells (SW480, SW48, DLD-
1 and HT29) (Figure 3A). RKO and SW480 cells were 
used to compare the mRNA expression of ATF3-related 
genes, and the results suggested that RKO, which had 
higher ATF3 protein expression, exhibited higher mRNA 
expression of DUSP14, HLF, and ULBP2. Moreover, 
a negative correlation between ATF3 expression and 
the expression of CEACAM1 and HDC was observed 
comparing RKO and SW480 cells (Figure 3B). Those 
two genes are functionally important in CRC progression. 
CEACAM1 is a metastasis-associated protein and histidine 
decarboxylase (HDC) is involved in the growth of colon 
tumors. Meanwhile, deleting ATF3 by CRISPR/Cas9 
genome editing in the ATF3 high-expressing cell lines 
(HCT116 and RKO) altered expression of ATF3 and its 
target genes, such as CEACAM1, DUSP14, HDC, HLF 
and ULBP2 (Figure 3C, 3D, 3E) may indicate the function 
in invasion and proliferation for further experiments.
Since the SW480 cell line had a lower ATF3 
protein expression than RKO, some relative genes may 
be expressed differently. In SW480, there originally 
is a lower expression of HLF mRNA and may not be 
reflected by a low ATF3 status, although it was elevated 
in both ATF3 CRISPR cells in RKO and HCT116. Gene 
expressions of the other 6 genes in our experiments were 
less dependent on ATF3 expression, which was shown in 
the Supplementary Figure 2. The ATF3 mRNA expression 
of these cell lines was also detected by qRT-PCR and 
consistently aligns with the results of ATF3 protein 
expression (Supplementary Figure 2).
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ATF3 regulated target genes as an oncogenic 
function
Cell proliferation, migration and invasion are the 
most important cell functions in the initial progression 
of cancer that relates with metastasis. To determine the 
contribution of ATF3 in CRC cell growth and motility, 
ATF3 CRISPR cells were assessed by wound healing assay 
and Transwell assay. There was no significant difference 
in cell proliferation in the first 24 h while ATF3 CRISPR 
cells grew more slowly in day 4 and 5 (Figure 4A). The 
migration of ATF3 CRISPR cells into the wounded area 
was significantly reduced compared to the control group 
(Figure 4B). RKO and HCT116 ATF3 CRISPR cells 
exhibited a significantly lower average velocity. These data 
demonstrated that ATF3 plays a key regulatory role in cell 
migration. The ATF3 CRISPR cells also exhibited reduced 
invasion ability by 50-60% compared to the control group 
(Figure 4C). These results showed that ATF3 regulates cell 
proliferation in vitro. Our RKO and HCT116 results were 
Figure 2: ATF3 presented binding motif in subset candidate genes. (A) Computational predicting binding sites of ATF3 and 
other transcription factors were shown in the up-stream of these genes. (B) Experimental results of ATF3 ChIP-seq and peaks for ATF3 
binding sites were show in Integrative Genomics Viewer (IGV).
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consistent with the other two independent studies, where 
ATF3 appeared to promote tumor growth and migration in 
HT29 cell line by either ATF3 antisense oligonucleotide 
or adenovirus-mediated overexpression of ATF3[16, 17].
The expression of ATF3 and its target genes 
correlated with major clinical parameters of 
CRC
To further study the potential clinical relevance of 
ATF3 to cancer progression, a TMA from CRC patients 
was developed to compare ATF3 expressions in CRC 
tissues and adjacent normal tissues. To confirm the 
specificity of the ATF3 antibody, we tested the ATF3 
antibody in mice colon tissues. ATF3 staining was present 
more intensely in the nucleus than in the cytoplasm and 
was undetected in ATF3 null mice, which suggested that 
the antibody specifically recognizes ATF3 in the tissues 
(Figure 5A). The whole slide image of the TMA was 
attached as Supplementary Figure 3, which makes the 
analysis of the IHC results more comparable since they 
were scanned simultaneously and automatically. In 81 
cases, higher ATF3 expression was observed in the CRC 
tissues compared to the adjacent normal tissues (28.3% 
vs. 0%, χ2=26.806, p<0.001; Supplementary Table 2 and 
Figure 5B, i). The ATF3 staining scores in clinical stages 
3 were significantly higher than that of stage 2 (Figure 5B, 
ii). However, the ATF3 expression of stage 1 and stage 4 
both seemed higher than that of stage 2 but there was no 
significant difference according to the results of unpaired 
t test, which may be due to the small sample sizes in stage 
1 and 4. In different clinical stages, ATF3 staining score 
was much higher in the tumor tissues than in the adjacent 
normal tissues using paired t tests (Figure 5C, 5D), which 
suggested that ATF3 expression increased significantly 
in the tumor tissue compared with the adjacent normal 
tissues. Although the average ATF3 staining score in stage 
3 and 4 were barely higher than that in stage 2 of Figure 
5D, scores in clinical stage 3 was significantly higher than 
that of stage 2 based on unpaired t testing with Welch’s 
correction analysis.
The association between ATF3 expression 
from the immunohistochemistry staining and the 
clinicopathological characteristics in CRC patients is 
summarized in Table 1. A Pearson χ2 analysis showed a 
significant correlation between ATF3 expression and the 
clinical stage (p=0.020), N stage (p=0.020), and patient 
survival status (p=0.039). However, no significant 
correlation was found between ATF3 expression and other 
clinical features, such as age, gender, tumor size, etc.
To test whether ATF3 expression might be a 
prognostic predictor in CRC, we used a Cox regression 
analysis to examine ATF3 expression and other 
clinicopathological characteristics with OS in 81 CRC 
patients. A univariate analysis indicated that ATF3 
expression (HR 0.454; 95% CI 0.252-0.817; p=0.008), 
clinical stage (HR 2.354; 95% CI 1.336-4.148; p=0.003), 
N stage (HR 2.230; 95% CI 1.539-3.497; p<0.001), M 
Figure 3: ATF3 regulated target genes. (A) Representative images of ATF3 expression in CRC cell lines: RKO and HCT116 
expressed higher ATF3 protein level by Western blot analysis. (B) CEACAM1, DUSP14, HDC, HLF and ULBP2 mRNAexpressions were 
detected by qRT-PCR analysis. (C) RKO and HCT116 cells were transfected with ATF3 sgRNA, without doxycycline hyclate treatment as 
sgRNA CRISPR control, and with doxycycline hyclate treatment as CRISPR ATF3, which was confirmed by Western blot. (D, E) Silencing 
ATF3 caused changes in its target genes expressions by qRT-PCR analysis in HCT116 and RKO. Data represent mean ± SEM, (n=3). Paired 
t test in GraphPad Prism was used for data analysis. * represents p < 0.05. ** represents p < 0.01.
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stage (HR 9.851; 95% CI 2.233-43.466; p=0.003), and 
tumor size (HR 0.520; 95% CI 0.295-0.919; p=0.024) 
were significantly correlated with OS (Table 2). The 
number of patients in the M stage group was very small, 
and thus, a further multivariate analysis did not include the 
M stage analysis. The results of the multivariate analysis 
revealed that ATF3 expression, clinical stage and N stage 
might be independent prognostic indicators of OS in CRC 
patients. These findings indicate the possibility of using 
high expression levels of ATF3 as a predictor of prognosis 
and survival.
Evaluation of ATF3 and its target genes as a 
prognostic marker of CRC
ATF3 and its target genes were associated 
with poor prognosis. Survival data based on the 
immunohistochemistry results showed that high ATF3 
Figure 4: Functional characterization of ATF3 expression related to migration in CRC. (A) Cell proliferation was determined 
by PrestoBlue Kit. (i) Significant difference was found in the numbers of RKO Mock cells, Control CRISPR cells and ATF3 CRISPR cells 
on day 4 and day 5. (ii) Significant difference also was found in the numbers of HCT116 Mock cells, Control CRISPR cells and ATF3 
CRISPR cells on day 4 and day 5. (B) For wound healing assay, transfected cells were wounded by scratching and monitored over 24 
hours to determine the rate of wound closure. Representative images of triplicate experiments are shown [(B) (i) and (B) (iv)] (10x). Cell 
migration of RKO and HCT116 cell lines were assessed by measuring relative wound closure [(B) (ii) and (B) (v)] and average speed [(B) 
(iii) and (B) (vi)]. (C) The metastatic properties of RKO and HCT116 cell lines and their transfected cells. Three independent experiments 
with three fields for each were performed and representative fields were shown (10x). Data represent mean ± SEM, (n=3). Paired t test in 
GraphPad Prism was used for data analysis. * represents p < 0.05. ** represents p < 0.01.
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expression correlated with lower survival rates (p=0.008) 
(Figure 6A), and all the patients of different clinical stages 
had significantly different survival rates (p<0.001) (Figure 
6B).
11 ATF3 candidate genes were analyzed by a Cox 
regression analysis, which indicated that all the ATF3 
candidate genes were significantly associated with OS 
(Table 3) by a univariate analysis. Furthermore, 5 target 
genes of ATF3, including CEACAM1, DUSP14, HDC, 
HLF, and ULBP2, were highly related to OS in the 
clinical data (Figure 6C, 6D, 6E, 6F, 6G). Low levels of 
CEACAM1, HDC, and HLF expression were associated 
with poor prognosis (CEACAM1 p=0.019; HDC p=0.017; 
HLF p=0.016). However, high levels of DUSP14 and 
ULBP2 were also related to a low survival rate of the 
patients (DUSP14 p=0.042; ULBP2 p=0.005). The Kaplan 
Figure 5: ATF3 is upregulated and positively correlated with stage in CRC. (A) ATF3 immunohistochemical staining images 
of colon tissues from Wild type (WT) and ATF3 null (KO) mice (20x). (B) (i) ATF3 staining scores of CRC tumor tissues and adjacent 
normal tissues from TMA. (ii) ATF3 staining scores of CRC tumor tissues in different clinical stages. Paired t test in GraphPad Prism was 
used for analysis in (B) (i) and unpaired t test with Welch’s correction in GraphPad Prism was used for analysis in (B) (ii). ** represents p 
< 0.01. (C) ATF3 staining images of different clinical stages (40x). (D) ATF3 staining scores of tumor tissues and adjacent normal tissues 
in different clinical stages. Paired t test in GraphPad Prism was used to compare the differences between the ATF3 staining scores of tumor 
tissues and adjacent normal tissues. ** represents p < 0.01.
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Meier curve for overall survival rates assessed for the 
ATF3 mRNA expressions are shown in Supplementary 
Figure 4. There was no significant relevance between 
ATF3 mRNA expressions from the database and OS rate. 
A further multivariate analysis suggested that ULBP2 
(p=0.002), HDC (p=0.024) and HLF (p=0.022) were 
significant favorable prognostic genes of OS compared to 
the other ATF3 candidate genes. We also performed a Cox 
regression analysis taking stage as covariate, where most 
of the results were consistent with the previous study (data 
not shown).
DISCUSSION
CRC is associated with a high recurrence and a 
high mortality rate due to lack of knowledge about the 
Table 1: Association between ATF3 expression and clinicopathological characteristics in colon cancer patients
Characteristic n ATF3- (%) ATF3+ (%) Pearson χ2 p value
Total 81
Gender 0.100 0.752
 Male 41 30 (73.17) 11 (26.83)
 Female 40 28 (70.00) 12 (30.00)
Age 2.674 0.096
 <70 38 31 (81.58) 7 (18.42)
 ≥70 43 28 (65.12) 15 (34.88)
Clinical stage 5.391 0.020*
 I+II 48 39 (81.25) 9 (18.75)
 III+IIII 33 19 (57.58) 14 (42.42)
T stage 1.283 0.257
 T1+T2 9 5 (55.56) 4 (44.44)
 T3+T4 72 53 (73.61) 19 (26.39)
N stage 5.391 0.020*
 N0 48 39 (81.25) 9 (18.75)
 N1+N2 33 19 (57.58) 14 (42.42)
M stage 0.471 0.493
 M0 79 57 (72.15) 22 (27.85)
 M1 2 1 (50.00) 1 (50.00)
Patient status 4.234 0.039*
 live 32 27 (84.38) 5 (15.62)
 death 49 31 (63.27) 18 (36.73)
Tumor size 0.031 0.86
 <37.5 40 29 (72.50) 11 (27.50)
 ≥37.5 41 29 (70.73) 12 (29.27)
Tumor site 0.995 0.803
Right hemicolon 27 19 (70.37) 8 (29.63)
Transverse colon 13 8 (61.54) 5 (38.46)
Left hemicolon 12 9 (75.00) 3 (25.00)
Sigmoid colon 29 22 (75.86) 7 (24.14)
* p < 0.05, ** p < 0.01.
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gene signatures related to its pathogenic development. 
Thus, identifying key transcription factors that regulate 
the molecular signature associated with CRC progression 
will be useful. Here, an integrative strategy was used to 
comprehensively analyze the variable patterns of CRC 
based on RNA-Seq, ChIP-Seq, TMA, gene profiling and 
molecular signature. We studied the clinical and functional 
significance of ATF3 expression in CRC. An analysis of 
TMA showed that an increased ATF3 expression was 
related with CRC progression and a reduced survival rate 
in CRC patients. Correspondingly, depletion of ATF3 
in high metastatic potential CRC cell lines decreased 
cell migration and proliferation. In agreement with their 
increased motility, metastatic CRC cells are associated 
with controlled inhibition of the epithelial-mesenchymal 
transition (EMT). Moreover, the expression levels of 
ATF3 in CRC correlated with the expression of its target 
genes, such as CEACAM1, DUSP14, HDC, HLF and 
ULBP2, which are required for tumor cell invasion and 
proliferation and are robustly linked to poor prognosis in 
CRC.
ChIP-Seq and transcriptome analysis are 
progressively becoming available for molecular profiling 
in various cancers. The current challenge is to combine 
these various molecular biology information to obtain 
a more comprehensive and informative view of the key 
biological processes in cancer progression [18]. Our 
study aims to systematically analyze the RNA-Seq, 
ChIP-Seq, TMA, gene profiling and molecular signature 
of CRC cancer to get an insight of the main regulators 
and target genes in cancer. Our study first identified the 
DEGs between tumor and adjacent normal tissue mRNA 
expression in a large clinical patient cohort. These genes 
are filtered by the distance of TSS of ATF3 binding sites. 
Furthermore, our results suggested that the expressions of 
these target genes are more likely to be influenced by the 
ATF3 protein rather than mRNA (Figure 5). There was 
no significant relevance between ATF3 mRNA expression 
from database and OS. Here we focused on ATF3 protein 
expression in tumor cells, The TCGA mRNA expression 
came from mixed cell populations, which contributed to 
the ambiguity of expression due to subtype composition, 
especially for lower transcription factor expression. Next, 
we selected the transcription factor ATF3 and identified its 
targets using a filter method (Figure 1A). We showed that 
the pathway analysis result of CRC was consistent with 
known processes in CRC. In addition to this, we identified 
target genes that have not been previously reported and 
Table 2: Univariate and multivariate analysis of prognostic factors for overall survival in colon cancer patients
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
ATF3 expression
 High versus low 0.454 0.252-0.817 0.008** 0.462 0.224-0.875 0.018*
Gender
 Male versus female 0.723 0.410-1.273 0.261
Age (years)
 <70 versus ≥70 1.740 0.973-3.115 0.062
Clinical stage
 I + II versus III + IIII 2.354 1.336-4.148 0.003** 0.191 0.080-0.458 <0.001**
T
 T1+T2 versus T3+T4 1.266 0.501-3.196 0.618
N
 N0 versus N1+N2 2.230 1.539-3.497 <0.001** 0.308 0.127-0.746 0.009**
M
 M0 versus M1 9.851 2.233-43.466 0.003**
Tumor size
 <37.5 versus ≥ 37.5 0.520 0.295-0.919 0.024* 0.476 0.261-0.869 0.016
* p < 0.05, ** p < 0.01.
HR hazard ratio; 95% CI 95% confidence interval.
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able to depict their possible roles. In summary, combining 
data from different sources is a promising strategy to 
identify the main regulators and target genes of cancer.
Notably, the result of the KEGG pathway analysis 
suggested that the DEGs with a ATF3 binding motif 
were functionally enriched on a developmental process, 
and a correlation existed between development and 
carcinogenesis. Expression of these target genes had 
a strong association with the OS in the CRC patients 
Figure 6: molecular signature associates genes with their survival analysis. Overall survival curves by Kaplan-Meier 
method assessed for (A) ATF3 expression based on immunohistochemistry staining (p=0.007), (B) different clinical stages (p<0.001), (C) 
CEACAM1 mRNA expression (p=0.037), (D) DUSP14 mRNA expression (p=0.022), (E) HDC mRNA expression (p=0.015), (F) HLF 
mRNA expression (p=0.026), (G) ULBP2 mRNA expression (p=0.004). (A-B) were based on the results of immunohistochemistry. (C-G) 
were based on data from TCGA database.
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which was confirmed by Kaplan–Meier survival and Cox 
regression analyses (Figure 6 and Table 2, 3).
In the current study, with the expanded gene 
signatures, JASPAR database prediction identified ATF3 
as one of the top overrepresented transcription factors, 
along with another key transcription factor STAT3 (Figure 
2A). STAT3 is important and necessary for proliferation 
and survival in CRC-initiating cells [19]. Furthermore, 
these 11 gene signatures were validated in high ATF3-
expressing cell lines (HCT116 and RKO) by targeting 
ATF3 with CRISPR editing. We found that 5 genes, 
including CEACAM1, DUSP14, HDC, HLF and ULBP2, 
were either upregulated or downregulated by ATF3 
(Figure 3). Although 6 other genes, such as TOMM34, 
STC2, PARM1, SPTBN2, etc., had ATF3 binding motifs 
in their promoters, they were not regulated by ATF3 at 
least in these cell lines. TOMM34 is reportedly involved 
in the growth of cancer cells and may contribute to the 
development of novel anticancer drugs and diagnosis 
of CRCs based on the immunohistochemistry results of 
TOMM34 proteins in CRC tissues, which is more likely 
to be upregulated by amplification in CRC [20] rather 
than by transcriptional regulation through ATF3. Our data 
showed that the higher expression of ATF3 suppressed 
the carcinoembryonic antigen-related cell adhesion 
molecule 1 (CEACAM1) and hepatic leukemia factor 
(HLF). In addition, upregulated HDC and dual-specificity 
phosphatase 14 (DUSP14) are molecules that are related 
to cell adhesions with a low expression in the early stage 
of CRC, thus they act as tumor suppressors. However, 
CEACAM1 is elevated in metastatic CRC, suggesting 
a role change in CRC progression [21]. However, our 
results are consistent with our model systems in which 
ATF3-regulated CEACAM1 expression impacts metastatic 
Table 3: Univariate and multivariate analysis of target genes for overall survival in colon cancer patients
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
SPTBN2
Low versus high 0.671 0.453-0.994 0.045* 0.817 0.543-1.229 0.331
DUSP14
Low versus high 0.667 0.450-0.989 0.042* 0.743 0.496-1.114 0.151
CCNJL
Low versus high 1.488 1.005-2.204 0.046* 1.447 0.967-2.165 0.072
CEACAM1
Low versus high 1.597 1.076-2.37 0.019* 1.506 0.997-2.276 0.052
STC2
Low versus high 0.675 0.456-0.998 0.047* 0.706 0.472-1.056 0.090
ULBP2
Low versus high 0.569 0.383-0.845 0.005** 0.515 0.338-0.784 0.002**
TOMM34
Low versus high 0.642 0.432-0.954 0.027* 0.668 0.432-1.033 0.069
C20rf48
Low versus high 0.63 0.425-0.934 0.020* 0.734 0.486-1.108 0.141
PARM1
Low versus high 1.539 1.037-2.284 0.031* 1.295 0.854-1.965 0.224
HDC
Low versus high 0.615 1.088-2.427 0.017* 1.609 1.064-2.433 0.024*
HLF
Low versus high 0.615 1.092-2.424 0.016* 1.602 1.070-2.398 0.022*
* p < 0.05, ** p < 0.01.
HR hazard ratio; 95% CI 95% confidence interval.
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CRC cells and survival outcome. From experimentation, 
histamine can conduct proliferation and angiogenesis 
in these cancer cells. Our KEGG pathway analysis of 
the ATF3-regulated target genes indicated that histidine 
metabolism is important for oncogenesis. After deleting 
ATF3 in the RKO cells, HDC expression in vitro was 
elevated and suggested a negative correlation between 
ATF3 and HDC in our study. The absence or down 
regulation of HDC by inhibition of mature myeloid cells, 
led to a higher rate of colon carcinogenesis, and as a result 
of this, CRC patients have a lower amount of histamine 
catabolism in their colonic mucosae [22]. The growth 
of tumor allografts was promoted by HDC deficient 
immature myeloid cells in the mice model and immature 
myeloid cells are differentiated after getting exogenous 
histamine. Thus, they have the ability to suppress growing 
tumor allografts [23]. All the evidences were from the in 
vivo experiments. ATF3 regulating HDC expressions in 
myeloid cells that contributed to the tumor growths may 
need to be validated for in vivo experiments in further 
studies. DUSP14 is an important negative regulator of 
the mitogen-activated protein kinase (MAPK) signaling 
pathways, which are involved in inflammatory response, 
cancers, cell proliferation and differentiation [24]. 
Deleting ATF3 in RKO and HTC116 cells reduced the 
expression of DUSP14 and influenced the proliferation 
rate (Figure 4A). HLF is an output regulator of circadian 
rhythms and is aberrantly expressed in human cancers 
[25], and our results suggested that it might be related 
to a cell death program. The ULBP2 gene is a known 
ligand of the activating NK receptor NKG2D, and it is 
critically involved in tumor immunosurveillance. In the 
RKO cell line, ULBP2 was positively regulated by ATF3. 
On the other hand, ULBP2 showed negative regulation, 
which indicates that ATF3 both positively and negatively 
regulates its target genes. This effect is also dependent on 
its binding with other proteins. Recently, we identified that 
ATF3 interacted with HDACs for epigenetic regulation 
(unpublished data), which also showed positive and 
negative regulation depending on the different HDAC 
isoforms.
The controversial roles of ATF3 were demonstrated 
to occur in both oncogenesis and tumor suppression. The 
most striking studies supported an oncogenic role of ATF3 
based on correlative evidence of ATF3 overexpression 
in human cancer tissue [26]. The ATF3 expression is 
elevated in many human cancers, including breast, 
prostate, and Hodgkin lymphoma cancers. ATF3 may be 
oncogenic since it can protect cells from apoptosis and 
increase cell proliferation. Meanwhile, ATF3 can also 
promote metastasis of cell lines in vitro and in vivo by 
either overexpression or anti-sense/small interfering RNA 
knockdown [9]. When the ATF3 expression is expressed 
at lower levels in some cancers, such as esophageal 
squamous cell carcinoma and gastric cancer, ATF3 may 
act as a tumor suppressor [27]. ATF3 can also be induced 
through many anti-tumorigenic compounds, including a 
recently reported HDAC inhibitor [28] and non-steroidal 
anti-inflammatory drugs [29]. If ATF3 does act as a tumor 
suppressor, it may partially be due to the action of these 
compounds. However, after treating these compounds, 
the induction of ATF3 may result in deleterious effects if 
ATF3 acts as an oncogene [26]. ATF3 plays controversial 
roles both in oncogenesis and tumor suppression, which 
may be cell context dependent. In CRC models, ATF3 is a 
tumor suppressor through up-regulated heat-shock protein 
90 (Hsp90) inhibition tumor growth [30]. However, 
two independent studies showed that ATF3 appears to 
promote tumor growth and migration in the experimental 
HT29 colon cancer model by either ATF3 antisense 
oligonucleotide or adenovirus-mediated overexpression 
of ATF3[16, 17]. Previous studies investigated a limited 
number of cell lines and small cohorts that were not 
biologically relevant. Thus, to fully characterize the 
function of ATF3 in tumor progression in CRC, we used 
an integrative strategy from ChIP-Seq, a larger database 
of gene profiling, molecular signatures with OS outcome 
and a TMA. The TMA was assessed with a specific 
antibody for ATF3 that was tested in colon tissues from 
our wild type and ATF3 null mice. Compared to the 
adjacent normal tissues, ATF3 was different due to its 
elevation in the CRC specimens. ATF3 overexpression 
is associated with a regulatory molecular signature, and 
this signature is functionally related to the pathogenic 
development of CRC from TCGA. Eleven of the genes 
with a molecular signature had putative ATF3 regulatory 
elements within their promoter by ChIP-Seq. Within these 
target genes, we demonstrated that ATF3 regulated genes, 
such as CEACAM1, DUSP14, HDC, HLF and ULBP2 
are the novel target genes for ATF3, after conducting our 
CRISPR-Cas9 genome editing experiment. Subsequently, 
some target genes impacted the invasion and proliferation 
of tumor cells in vitro. However, some genes need to be 
further investigated in a tumor environment using ATF3 
knockout mice in CRC models to characterize the impact, 
such as HDC [22, 23].
Taken together, our results suggest that ATF3 
promotes the invasion and proliferation of CRC cells, at 
least in part, via the regulation of CEACAM1-mediated 
EMT. DUSP14, HDC, and HLF mediated cell metabolism 
and proliferation. These findings advocate that ATF3, 
coupled with its target genes, is a prognostic marker for 
CRC progression.
MATERIALS AND METHODS
Patient clinical data and RNA-Seq data
All the clinical information and the RNA-Seq data 
were downloaded from the TCGA data portal (https://gdc-
portal.nci.nih.gov/search/s?facetTab=cases). A total of 521 
CRC samples (41 normal and 480 tumor) were analyzed. 
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Two tumor samples were discarded in the subsequent 
analysis due to their incomplete clinical information. The 
RNA-Seq data for each sample was merged into a matrix 
containing counts of each Ensembl ID. The clinical data 
included gender, age, tumor stage, survival status, survival 
time and other demographic information (race, ethnicity, 
etc.).
DEG analysis
Before the DEG analysis, the RNA-Seq count matrix 
had 60,483 Ensembl IDs. We used the GTF file (Homo_
sapiens.GRCh38.86.chr) to obtain the gene symbol for 
each Ensembl ID, and 57,288 genes were kept for further 
study. The samples were separated into 4 groups by male/
female and tumor/normal. We used the limma package 
[31] (version 3.26.9) in RStudio (version 3.2.0) with 
the voom method, linear modeling and empirical Bayes 
moderation to assess the DEGs. The genes expressed in at 
least 40 samples (the number of the smaller group) with 
count per million (CPM) >1 were kept for the downstream 
analysis. We used a cut-off of log-fold-change (log2FC) 
>1 and a False Discovery Rate (FDR) <0.05 to determine 
the final DEGs. The KEGG pathway and GO analysis 
were conducted in RStudio (version 3.2.0).
Survival analysis for the DEGs
We used a Kaplan-Meier method on all the DEGs, 
using the median of the log-CPM to determine the 
high- and low-expression subgroups. We evaluated the 
significance of each subgroup by a log-rank test. The 
statistical analysis was performed with the RStudio 
survival package (version 2.40-1), and the P-value cut-off 
was set to 0.05.
ATF3 binding site predicting
The JASPAR database was used to predict the 
potential ATF3 binding sites. The JASPAR CORE database 
contains a curated, non-redundant set of profiles that are 
derived from published collections of experimentally 
defined transcription factor binding sites for eukaryotes.
ChIP-Seq data and peak annotation
The data from the ATF3 ChIP-Seq were downloaded 
from the GEO database (GSM1917774_1152) for the 
control group to identify the experimental ATF3 binding 
site. The ATF3-WT HCT116 colon cancer cell line was 
used for the ChIP analysis. The chromatin was sheared to 
an average fragment size of 500 bp by sonication using a 
Bioruptor and was immunoprecipitated using the indicated 
antibody. The sample was purified and sequenced using 
Illumina HiScanSQ following the protocols recommended 
by the manufacturer. The libraries were prepared according 
to Illumina’s instructions. The reads were aligned to the 
hg19 reference human genome using bwa v0.6.1, and 
peak calling was performed by HOMER v4.1 using the 
GRCh37 (hg19) human genome. Finally, we selected 
genes having a peak within a certain range from the TSS 
using the IGV [32].
TMA construction and cell lines
TMA of CRC tissues and adjacent tissues (HCol-
Ade180Sur-03 for CRC) from 90 patients was purchased 
from Shanghai Outdo Biotech (Shanghai, China) [33]. All 
of the protocols using human specimens were approved 
by the Shanghai Jiao Tong University, and informed 
consent was obtained from all of the subjects. The TMAs 
contained all the patients’ clinicopathological information, 
including the patients’ gender, age, tumor site and size, 
clinical stage, TNM stage and follow-up date (ended in 
December 2011). Nine patients were excluded due to the 
inadequate completion of follow-up data and tissues. In 
total, 81 patients were included, with 41 males and 40 
females of a median age of 70 (ranging from 24 to 90). 
The OS time ranged from 3 to 96 months. The TMAs 
were prepared and processed for immunostaining using an 
ATF3 (Santa Cruz, USA) antibody. The human colon cell 
lines SW480, SW48, DLD-1, HCT116, RKO and HT29 
were purchased from ATCC (Manassas, VA). All of the 
cell lines were grown in RPMI-1640 medium with 10% 
fetal bovine serum (FBS) and 1% penicillin/streptomycin 
at 37°C with 5% CO2 in a cell culture incubator.
Immunohistochemistry
Five-micrometer-thick TMA sections were 
deparaffinized in xylene and hydrated in a series of graded 
ethanol. Antigen retrieval was completed after heating in 
citrate buffer (pH 6.0) in a pressure cooker for 15 min. 
Endogenous peroxidases were blocked by 3% H2O2 for 10 
min, and the sections were then incubated with goat serum 
for 20 min at room temperature. The slides were incubated 
with the ATF3 primary antibody (1:500 dilution in 1% 
bovine serum albumin PBS solution) at 4oC overnight 
and was then incubated with horseradish peroxidase 
(HRP) (Vectastain ABC kit, USA) for 30 min at room 
temperature. Finally, the slides were incubated with the 
ABC reagent for another 30 min at room temperature for 
signal amplification, washed with TBST and stained using 
3, 3’-diaminobenzidine (DAB).
The staining results were scored by two pathologists 
blinded to the clinical data, and the staining was classified 
into four grades based on the staining intensity as follows: 
0, no cell staining; 1, weak staining; 2, moderate staining; 
and 3, strong staining. The proportion of positively stained 
cells was classified into four levels as follows: level 1 
(<25%); level 2 (25%-50%); level 3 (50%-75%); and 
level 4 (>75%). The final immunohistochemistry score 
was obtained by multiplying the intensity and proportion 
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values (range 0-12), and the samples were grouped as 0 
(score 0), 1 (score 1-3), 2 (score 3-6), 3 (score 6-9) and 4 
(score 9-12) staining. For statistical purposes, final scores 
of 3 and 4 were defined as high expression and other 
scores as low expression.
CRISPR
The MIT CRISPR design software was used to design 
the sgRNAs (http://crispr.mit.edu). The sgRNA ATF3 
sequence was TCCCACTGTCAGCGACAGACCCCT. 
The lentiviral particles were produced by transient 
transfection of 293T cells grown in 10-cm Petri dishes 
with 10 μg of vector DNA containing a pFgh1tUTG vector 
with the target sgRNA inserted and the pFUCas9mCherry 
vector, which was gift from Marco Herold [34], along with 
the packaging constructs pMDL, pRSV-rev, and pVSV-G 
using standard calcium phosphate precipitation. The virus-
containing supernatants were collected 48–72 h after 
transfection. To establish the ATF3 knockdown, HCT116 
and RKO cells were treated with 8 ng/ml polybrene in 
the viral supernatant, and doxycycline hyclate (Sigma-
Aldrich) was used to treat the cell lines to induce the 
expression of ATF3 sgRNA for 3 days. Cells without 
doxycycline hyclate treatment were used as the sgRNA 
control.
Proliferation assay
The effect of ATF3 CRISPR on cellular growth and 
proliferation was determined in vitro using the PrestoBlue 
kit (Invitrogen, USA). Two thousand cells were seeded 
into 96-well plates with RPMI-1640 medium in a volume 
of 90 µl. After incubation, 10 µl of PrestoBlue reagent 
was added to each well, and after 30 min, the absorbance 
was read at a wavelength of 570 nm using a microplate 
spectrophotometer (BMG Labtech, Germany).
Wound healing and invasion assays
Cell migration activity was assessed by a wound 
healing assay. Briefly, 105 cells were seeded into 24-
well plates and were incubated until they reached 90% 
confluency. The cells were starved for 24 h and were 
wounded by scratching lines with a 200-μl pipette tip. 
Cells were washed with PBS twice to remove the debris, 
then the cells were observed and photographed under a 
microscope. The images were recorded after 24 h and 48 
h. A cell invasion assay was performed using Transwell 
chambers (24 well, 8 μm pore size, Corning, NY). In the 
assay, 600 μl of RPMI-1640 medium containing 20% FBS 
was used as the attractant in the lower chamber, and 100 μl 
of RPMI-1640 medium containing 5 × 105 cells was added 
to the upper chamber; the cells were allowed to migrate 
through the pores. The cells on the lower side of the insert 
filter were fixed with 4% paraformaldehyde for 10 min 
and were stained with 0.1% crystal violet for 15 min. The 
numbers of cells on the underside of the filter from three 
randomly selected microscopic views were counted and 
photographed.
Western blotting
Western blotting was performed using primary 
antibodies against ATF3 (1:500 dilution, Santa Cruz, 
USA) and actin (1: 10,000 dilution, Sigma, USA). The 
secondary antibodies were goat anti-rabbit IgG (1: 5,000 
dilution, Invitrogen, USA) and goat anti-mouse IgG (1: 
5,000 dilution, Invitrogen, USA) [35].
Quantitative real-time PCR analysis
The quantitative real-time PCR analysis of the 
expression of SPTBN2, DUSP14, CCNJL, CEACAM1, 
HLF, STC2, ULBP2, HDC, TOMM34, PARM1 and 
C2orf48 was performed in triplicate on an Applied 
Biosystems 7700 Prism real-time PCR machine with 
SYBR Green QPCR mix and each gene probe. The 
expression of the target genes was normalized to the 
expression of the housekeeping gene 18S. To calculate 
fold change, the data were transformed using the 
‘relative standard curve method and comparative 
threshold cycle (Ct) method (Δ ΔCt)’ as described by 
Applied Biosystems.
Statistical analysis
The statistical analysis was performed using 
SPSS version 16.0 for Windows. A Kaplan-Meier plot 
and log-rank tests were used for the survival analysis. 
Univariate and multivariate Cox regression models were 
used to analyze the independent prognostic factors and 
the ATF3 candidate genes. The associations between 
ATF3 expression and the clinicopathological features 
were analyzed by Pearson’s chi-square (χ2) test. The 
differences were considered significant at a value of p 
<0.05 [36, 37].
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